Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2121

Sort by

Sort Order Select

Journal Articles

Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma

Wendan Xu, Philipp Berning, Georg Lenz

Blood (2021) 138 (13): 1110–1119.

https://doi.org/10.1182/blood.2020006784

Published: 2021

Journal Articles

Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma

Ana Silva, Afonso R. M. Almeida, Ana Cachucho, João L. Neto, Sofie Demeyer, Mafalda de Matos, Thea Hogan, Yunlei Li, Jules Meijerink, Jan Cools, Ana Rita Grosso, Benedict Seddon, João T. Barata

Blood (2021) 138 (12): 1040–1052.

https://doi.org/10.1182/blood.2019000553

Published: 2021

Includes: Supplemental data

Journal Articles

Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis

Jia-feng Wang, Yun-peng Wang, Jian Xie, Zhen-zhen Zhao, Sahil Gupta, Yu Guo, Song-hui Jia, Jean Parodo, John C. Marshall, Xiao-ming Deng

Blood (2021) 138 (9): 806–810.

https://doi.org/10.1182/blood.2020009417

Published: 2021

Includes: Supplemental data

Journal Articles

FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia

Blood (2021) 138 (9): 758–772.

https://doi.org/10.1182/blood.2020008101

Published: 2021

Includes: Supplemental data

Journal Articles

CLL cells are moved by the MARCKS brothers

Jan A. Burger

Blood (2021) 138 (7): 503–504.

https://doi.org/10.1182/blood.2021011650

Published: 2021

Journal Articles

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia

Ishwarya Murali, Siddha Kasar, Aishath Naeem, Svitlana Tyekucheva, Jasneet K. Khalsa, Emily M. Thrash, Gilad Itchaki, Dimitri Livitz, Ignaty Leshchiner, Shuai Dong, Stacey M. Fernandes, Gad Getz, Amy Johnson, Jennifer R. Brown

Blood (2021) 138 (1): 44–56.

https://doi.org/10.1182/blood.2020006765

Published: 2021

Includes: Supplemental data

Journal Articles

PI3K/BCL2: illusion or promise for RS?

Lukas P. Frenzel

Blood (2021) 137 (24): 3319–3321.

https://doi.org/10.1182/blood.2021011854

Published: 2021

Journal Articles

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

Blood (2021) 137 (20): 2817–2826.

https://doi.org/10.1182/blood.2020007376

Published: 2021

Includes: Supplemental data

Journal Articles

Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL

Blood (2021) 137 (18): 2463–2480.

https://doi.org/10.1182/blood.2019004547

Published: 2021

Includes: Supplemental data

Journal Articles

CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1

Roger Belizaire, Sebastian H. J. Koochaki, Namrata D. Udeshi, Alexis Vedder, Lei Sun, Tanya Svinkina, Christina Hartigan, Marie McConkey, Veronica Kovalcik, Amanuel Bizuayehu, Caroline Stanclift, Monica Schenone, Steven A. Carr, Eric Padron, Benjamin L. Ebert

Blood (2021) 137 (16): 2209–2220.

https://doi.org/10.1182/blood.2020006528

Published: 2021

Includes: Supplemental data

Journal Articles

The metabolic enzyme pyruvate kinase M2 regulates platelet function and arterial thrombosis

Manasa K. Nayak, Madankumar Ghatge, Gagan D. Flora, Nirav Dhanesha, Manish Jain, Kathleen R. Markan, Matthew J. Potthoff, Steven R. Lentz, Anil K. Chauhan

Blood (2021) 137 (12): 1658–1668.

https://doi.org/10.1182/blood.2020007140

Published: 2021

Includes: Supplemental data

Journal Articles

Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia

Lili Song, Bo Yu, Yi Yang, Jianwei Liang, Yingwen Zhang, Lixia Ding, Tianyi Wang, Xinyu Wan, Xiaomin Yang, Jingyan Tang, Shengyue Wang, Benshang Li, Yanxin Li, Haizhong Feng

Blood (2021) 137 (9): 1181–1191.

https://doi.org/10.1182/blood.2020005622

Published: 2021

Includes: Supplemental data

Journal Articles

Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL

Lorena Fontan, Rebecca Goldstein, Gabriella Casalena, Matthew Durant, Matthew R. Teater, Jimmy Wilson, Jude Phillip, Min Xia, Shivem Shah, Ilkay Us, Himaly Shinglot, Ankur Singh, Giorgio Inghirami, Ari Melnick

Blood (2021) 137 (6): 788–800.

https://doi.org/10.1182/blood.2019004713

Published: 2021

Includes: Supplemental data

Journal Articles

Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma

Anne Durandy, Sven Kracker

Blood (2020) 135 (9): 638–643.

https://doi.org/10.1182/blood.2019002072

Published: 2020

Journal Articles

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Matthew Lunning, Julie Vose, Loretta Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Susan O’Brien

Blood (2019) 134 (21): 1811–1820.

https://doi.org/10.1182/blood.2019002118

Published: 2019

Includes: Supplemental data

Journal Articles

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Zachary Davis, PhD BS, Martin Felices, PhD, Todd R Lenvik, Sujan Badal, Peter Hinderlie, Bruce R. Blazar, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 621.

https://doi.org/10.1182/blood-2019-127261

Published: 2019

Journal Articles

Oncogenic Mechanisms of CBL E3 Ubiquitin Ligase Mutations in Myeloid Malignancies

Roger Belizaire, MD PhD, Sebastian Koochaki, BS, MS, Namrata Udeshi, PhD, Alexis Vedder, BS, Lei Sun, Monica Schenone, PhD, Steven Carr, PhD, Eric Padron, MD, Benjamin L. Ebert, MD PhD

Blood (2019) 134 (Supplement_1): 563.

https://doi.org/10.1182/blood-2019-122503

Published: 2019

Journal Articles

Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling

Leandro Cerchietti, MD, Giorgio Inghirami, MD, Nikita Kotlov, PhD, Viktor Svekolkin, PhD, Alexander Bagaev, PhD, Felix Frenkel, PhD, Maria Victoria Revuelta, PhD, Jude M Phillip, PhD, Maria Teresa Cacciapuoti, MS, Sarah C. Rutherford, MD, Peter Martin, FRCPC, MD MS, John P. Leonard, MD

Blood (2019) 134 (Supplement_1): 656.

https://doi.org/10.1182/blood-2019-128889

Published: 2019

Journal Articles

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Anthony R. Mato, MDMSCE, Lindsey E. Roeker, MD, Toby A. Eyre, MBBChir, MRCP, Ryan Jacobs, MD, Brian T. Hill, MD, Nicole Lamanna, MD, Danielle M. Brander, MD, Mazyar Shadman, MD, Chaitra Ujjani, MD, Maryam Yazdy, MD, Guilherme Fleury Perini, MD, Javier Pinilla Ibarz, MD PhD, Jacqueline C Barrientos, MD, Alan Skarbnik, MD, Pallawi Torka, MD, Jeffrey J Pu, MD PhD, John M. Pagel, MD PhD DSc, Satyen Gohil, BSc, MBBS, MRCP, FRCPath, Bita Fakhri, MDMPH, Michael Y. Choi, MD, Catherine C. Coombs, MD, Joanna Rhodes, MD, Paul M. Barr, MD, Craig A. Portell, MD, Helen Parry, MB ChB, MRCP, PhD, Christine Ann Garcia, MD MPH, Kate J Whitaker, BA, Allison M. Winter, MD, Andrea Sitlinger, MD, Sirin Khajavian, MD, Ariel F Grajales-Cruz, MD, Krista Isaac, DO, MS, Pratik Shah, Othman S. Akhtar, MD, Rachael Pocock, MD, Kentson Lam, MD PhD, Timothy J Voorhees, MD, Stephen J. Schuster, MD, Thomas David Rodgers, MD, Nicolas Martinez-Calle, MD MSc, Talha Munir, MD, Erica B Bhavsar, BS, Neil Bailey, MSc, Jason C. Lee, MD, Hanna Weissbrot, BS, Chadi Nabhan, MDMBA, FACP, Julie Goodfriend, Amber C. King, PharmD, BCOP, Andrew D. Zelenetz, MD PhD, Colleen Dorsey, BSN, RN, Kayla Bigelow, Bruce D. Cheson, MD, Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD, John N. Allan, MD

Blood (2019) 134 (Supplement_1): 502.

https://doi.org/10.1182/blood-2019-123747

Published: 2019

Journal Articles

Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN)

Manjola Balliu, PhD, Laura Calabresi, PhD, Niccolò Bartalucci, PhDBSc, Laura Maggi, PhD, Francesco Annunziato, PhD, Paola Guglielmelli, MD PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 471.

https://doi.org/10.1182/blood-2019-123685

Published: 2019

NARROW

Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma

Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma

Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis

FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia

CLL cells are moved by the MARCKS brothers

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia

PI3K/BCL2: illusion or promise for RS?

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL

CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1

The metabolic enzyme pyruvate kinase M2 regulates platelet function and arterial thrombosis

Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia

Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL

Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Oncogenic Mechanisms of CBL E3 Ubiquitin Ligase Mutations in Myeloid Malignancies

Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only